Frankfurt - Delayed Quote EUR
Lipigon Pharmaceuticals AB (publ) (9RP.F)
As of 8:13 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
9,327.0000
16,407.0000
--
3,180.0000
4,278.0000
--
Operating Expense
29,759.0000
28,779.0000
37,742.0000
44,371.0000
12,102.0000
--
Operating Income
-20,432.0000
-12,372.0000
-37,742.0000
-41,191.0000
-7,824.0000
--
Net Non Operating Interest Income Expense
177.0000
243.0000
37.0000
78.0000
7.0000
--
Pretax Income
-20,255.0000
-12,128.0000
-37,705.0000
-41,113.0000
-8,068.0000
--
Net Income Common Stockholders
-20,255.0000
-12,128.0000
-37,705.0000
-41,113.0000
-8,068.0000
--
Diluted NI Available to Com Stockholders
-20,255.0000
-12,128.0000
-37,705.0000
-41,113.0000
-8,068.0000
--
Basic EPS
-0.26
-0.19
-2.12
-3.35
-0.64
--
Diluted EPS
-0.26
-0.19
-2.12
-3.35
-0.64
--
Basic Average Shares
105,696.6340
64,121.1850
17,790.7110
12,271.1170
12,526.0110
--
Diluted Average Shares
105,696.6340
64,121.1850
17,790.7110
12,271.1170
12,526.0110
--
Total Operating Income as Reported
-20,432.0000
-12,371.0000
-37,742.0000
-41,191.0000
-7,824.0000
--
Total Expenses
29,759.0000
28,779.0000
37,742.0000
44,371.0000
12,102.0000
--
Net Income from Continuing & Discontinued Operation
-20,255.0000
-12,128.0000
-37,705.0000
-41,113.0000
-8,068.0000
--
Normalized Income
-20,255.0000
-12,128.0000
-37,705.0000
-41,113.0000
-7,817.0000
--
Interest Income
238.0000
246.0000
37.0000
83.0000
10.0000
--
Interest Expense
61.0000
3.0000
--
5.0000
3.0000
--
Net Interest Income
177.0000
243.0000
37.0000
78.0000
7.0000
--
EBIT
-20,194.0000
-12,125.0000
-37,705.0000
-41,108.0000
-8,065.0000
--
EBITDA
-20,169.8000
-12,101.0000
-37,681.0000
-41,085.0000
-8,065.0000
--
Reconciled Depreciation
24.2000
24.0000
24.0000
23.0000
--
--
Net Income from Continuing Operation Net Minority Interest
-20,255.0000
-12,128.0000
-37,705.0000
-41,113.0000
-8,068.0000
--
Total Unusual Items Excluding Goodwill
--
--
--
--
-251.0000
-52.0000
Total Unusual Items
--
--
--
--
-251.0000
-52.0000
Normalized EBITDA
-20,169.8000
-12,101.0000
-37,681.0000
-41,085.0000
-7,814.0000
--
12/31/2019 - 3/3/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LYTIX.OL Lytix Biopharma AS
6.20
+1.64%
ACE.ST Ascelia Pharma AB (publ)
2.1700
-1.59%
FLUI.ST Fluicell AB (publ)
0.0758
+2.99%
ORPHA.CO Orphazyme A/S
1,185.00
-4.70%
AVTE Aerovate Therapeutics, Inc.
2.3700
+2.16%
HNSA.ST Hansa Biopharma AB (publ)
41.36
+2.12%
EXPRS2.ST ExpreS2ion Biotech Holding AB (publ)
0.9180
+2.46%
LYRA Lyra Therapeutics, Inc.
0.2436
+4.64%
CYCC Cyclacel Pharmaceuticals, Inc.
1.1400
+12.87%
TNXP Tonix Pharmaceuticals Holding Corp.
0.1800
+0.33%